Form 4: Mira Pharmaceuticals Director Acquires Stock Options

Sentiment:

SEC Form 4 Filing


Director Edward Clouston MacPherson acquired nonqualified stock options in Mira Pharmaceuticals, with a portion vesting immediately.

Summary

  • On March 25, 2024, Edward Clouston MacPherson, a director of Mira Pharmaceuticals, acquired 50,000 nonqualified stock options.
  • The exercise price of these options is $1.16.
  • 25,000 of these options vested immediately, while the remaining 25,000 will vest on March 25, 2025.
  • Following the transaction, MacPherson beneficially owns 25,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction (granting of stock options) and doesn't inherently indicate positive or negative performance.

Positives

  • The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Stock options are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with those of shareholders.

Stakeholder Impact

  • The granting of stock options could potentially align the director's interests more closely with those of the shareholders.

Key Dates

DateDescription
03/25/2024Date of transaction: Director acquired stock options; 25,000 options vested immediately.
03/25/2025Date of vesting: Remaining 25,000 stock options vest.
03/25/2034Expiration date of the stock options.
03/27/2024Date of Form 4 signature.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.